Quick Answer
VYNE Therapeutics Inc. reported Earnings Per Share Diluted of $0.62 (loss) per share for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +33.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $4.83 (loss) per share | Q3 2020: $0.59 (loss) per share | Q1 2021: $0.42 (loss) per share | Q2 2021: $0.39 (loss) per share | Q3 2021: $0.41 (loss) per share | Q1 2022: $1.51 per share | Q2 2022: $2.63 (loss) per share | Q3 2022: $2.94 (loss) per share | Q1 2023: $1.74 (loss) per share | Q2 2023: $3.09 (loss) per share | Q3 2023: $2.01 (loss) per share | Q1 2024: $0.15 (loss) per share | Q2 2024: $0.22 (loss) per share | Q3 2024: $0.29 (loss) per share | Q1 2025: $0.20 (loss) per share | Q2 2025: $0.13 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), VYNE Therapeutics Inc.'s Earnings Per Share Diluted has declined by 107.9%.
- Historical annual values: Fiscal year 2025: $0.62 (loss) per share | Fiscal year 2024: $0.93 (loss) per share | Fiscal year 2023: $2.78 (loss) per share | Fiscal year 2022: $7.28 (loss) per share | Fiscal year 2021: $25.64 (loss) per share | Fiscal year 2020: $7.88 per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: